Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anbio Biotechnology Class A Ordinary Shares (NNNN)
Frankfurt am Main, DE
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09% | +11.00% | +20.74% | +33.58% | +46.86% | +14.43% | +334.47% | +496.36% | +496.36% | +496.36% | +496.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Instruments & Supplies: +7.9%+19.2% ★ Q4'25: +19.9% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+185.7% ★ Q4'25: +270.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-68.7% Q4'25: +33.9% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+66.7% ★ Q4'25: +59.1% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+35.7% ★ Q4'25: +61.3% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+3.8% Q4'25: +3.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.00× ★ Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 25.8K +— (+0.0%) | 661.9K -112.8K (-14.6%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD17.51 +46.7% | 5 qtrs — |
| 2 | BNP PARIBAS ARBITRAGE, SNC | 10.4K +9.4K (+940.0%) | 267.2K +237.1K (+788.5%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD26.52 -3.1% | 4 qtrs — |
| 3 | MORGAN STANLEY | 7.3K +7.3K (+26,107.1%) | 188.5K +187.7K (+22,288.7%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD25.73 -0.2% | 4 qtrs — |
| 4 | UBS GROUP AG | 6.3K +3.5K (+122.5%) | 162.8K +77.2K (+90.1%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD25.93 -0.9% | 5 qtrs — |
| 5 | EVERSOURCE WEALTH ADVISORS, LLC | 266.00 +266.0 (+100.0%) | 6.8K +6.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD25.69 +0.0% | 1 qtrs NEW |
| 6 | WELLS FARGO & COMPANY/MN | 100.00 +— (+0.0%) | 2.6K -438.0 (-14.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD31.66 -18.9% | 4 qtrs — |
| 7 | BARE FINANCIAL SERVICES, INC | 15.00 +15.0 (+100.0%) | 385.00 +385.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD25.67 +0.1% | 1 qtrs NEW |
| 8 | RONALD BLUE TRUST, INC. | 5.00 +5.0 (+100.0%) | 128.00 +128.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD25.60 +0.4% | 1 qtrs NEW |
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | XU CANY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | TIAN CHRIS | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Song Suki | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | LAU MICHAEL | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Hartzler Nancy | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Lau | Chief Executive Officer | 250.0K | male |
| Chris Tian | Chief Business Officer | 113.7K | male |
| Suki Song | Chief Financial Officer | 100.0K | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NNNN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
